BioStock: PHI aims for US listing

July 11, 2024

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

PHI-at-analyst-group-interview-anders-mansson

December 6, 2024

Analyst Group Intervju med PHIs VD Anders Månsson

Analyst Group intervjuar Anders Månsson, VD för Phase Holographic Imaging, i samband med bolagets företrädesemission år 2024.

Biostock-Phase-Holographic-Imaging-1280px-Anders-Goran

December 3, 2024

BioStock: Studio interview with Anders Månsson and Goran Dubravčić

Recently, PHI welcomed Anders Månsson as its new CEO. In a video interview, Månsson and Chairman of the Board Goran Dubravčić discuss the company’s future strategy and the ongoing rights issue.

phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

November 6, 2024

BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.

PHI-accelerates-growth-with-record-order-biostock

October 2, 2024

BioStock: PHI accelerates growth with record order

PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.

1 234 5…10